Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?

Abstract

BACKGROUND Androgen-deprivation therapy (AD), in the form of gonadotropin-releasing hormone agonists, is commonly used as an adjunctive treatment in patients with prostate cancer. Its use in this setting is based on data collected when prostate cancer was generally detected at a more advanced stage, and outcomes were poor. Since the advent of widespread PSA screening, prostate cancer is usually diagnosed at an earlier stage; most patients present with LOWRISK or INTERMEDIATE-RISK disease, and treatment outcomes have improved. The use of AD in this new setting has not been properly investigated.

DOI: 10.1038/ncponc0168

Cite this paper

@article{Miyamoto2005DoesAD, title={Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?}, author={Hiroshi Miyamoto and Edward Messing and Chawnshang Chang}, journal={Nature Clinical Practice Oncology}, year={2005}, volume={2}, pages={236-237} }